Poetics/Poelitics of materiality in latin american digital poetry

Este artículo propone leer la poesía digital latinoamericana en vinculación con el acontecimiento poético-político que emerge cuando se considera su materialidad. Dar visibilidad a la materialidad habilita limitar la naturalización de los sentidos que vienen asociados a la cultura digital hegemónica contemporánea. Esto se logra desde procedimientos que ponen de relieve tanto los diversos niveles de materialidad inherentes a cada evento artístico literario digital —materialidad textual de superficie, materialidad relacional de las interfaces tanto de software como de hardware, materialidad del código— como los modos convencionales de ser con y hacer sentido de los entramados técnicos digitales que organizan nuestra vida cotidiana.This paper aims to read Latin American digital poetry in regards to the poetic-political event that emerges whenever its materiality is considered. To make materiality visible enables one to restrict the naturalization of meanings associate with contemporary hegemonic digital culture. This is accomplished through artistic procedures that emphasize, on the one hand, the multiple levels of materiality inherent to digital literary works— surface/textual materiality, software and hardware interface relational materiality, code materiality—and, on the other hand, the conventional ways to interact with and build meaning within the digital space that organize everyday life.Fil: Kozak, Claudia. Universidad de Buenos Aires. Facultad de Ciencias Sociales. Instituto de Investigaciones "Gino Germani". Estudios Culturales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Tres de Febrero; Argentin

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years